Ironwood Pharmaceuticals (IRWD) Asset Writedowns and Impairment (2014 - 2018)

Ironwood Pharmaceuticals has reported Asset Writedowns and Impairment for 4 years, with the latest figure at $2.5 million in Q3 2018.

• Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $2.5 million in Q3 2018, while the trailing twelve-month figure through Sep 2019 was $4.3 million (changed 0.0% YoY) and the FY2018 annual result came in at $151.8 million, changed N/A from the prior year.
• Asset Writedowns and Impairment grew to $2.5 million in Q3 2018 per IRWD's latest filing, from $1.8 million in the prior quarter.
• Over five years, Asset Writedowns and Impairment peaked at $11.4 million in Q4 2014 and troughed at $1.8 million in Q2 2018.
• A 4-year average of $6.6 million and a median of $7.0 million in 2014 frame the typical range for Asset Writedowns and Impairment.
• The widest YoY moves for Asset Writedowns and Impairment: up 43.82% in 2015, down 43.82% in 2015.
• Over 4 years, Asset Writedowns and Impairment stood at $11.4 million in 2014, then sank by 56.14% to $5.0 million in 2015, then soared by 102.0% to $10.1 million in 2016, then tumbled by 75.25% to $2.5 million in 2018.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $2.5 million, $1.8 million, and $10.1 million for Q3 2018, Q2 2018, and Q4 2016 respectively.